THE IN-VITRO ACTIVITY OF GREPAFLOXACIN AGAINST CHLAMYDIA SPP., MYCOPLASMA SPP., UREAPLASMA-UREALYTICUM AND LEGIONELLA SPP

The activity of grepafloxacin, a new orally active fluoroquinolone, wa s compared with the activities of ofloxacin, clarithromycin and doxycy cline against Chlamydia pneumoniae, Chlamydia trachomatis, Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum, and with th e activities of ofloxacin, clarithromycin and rifampicin against Legio nella spp. Grepafloxacin (MIC range 0.06-0.12 mg/L) was some 8-16 time s more active than ofloxacin against the chlamydiae, showing activity similar to that of doxycycline, and equal or two-to four-fold less act ive than clarithromycin. Grepafloxacin was four-fold more active than ofloxacin against M. pneumoniae (MIG 0.06-0.5 mg/L) and U. urealyticum (MIG 0.12-1.0 mg/L), but 16 times more active against M. hominis (MIG 0.015-0.05 mg/L). Grepafloxacin was highly active against Legionella spp. (MIG 0.008-0.03 mg/L), showing equivalent activity to ofloxacin, clarithromycin and rifampicin.